Here are four things to know.
- 1.RespirTech develops electronic-pulsating vests for patients with respiratory diseases such as chronic obstructive respiratory disease and cystic fibrosis. The vests, which cost $12,000 to $15,000, help patients clear their lungs by regularly inflating and deflating to improve circulation.
- James Ehlen, MD, RespirTech’s CEO, expects Amsterdam-based Philips to significantly scale out the business, which is on track to earn $50 million in revenue this year.
- RespirTech employs 200 people, and Dr. Ehlen said a few administrative positions may be cut following the deal.
- The deal is expected to close within several months.
More articles on supply chain:
McKesson 2017 revenue up 4%: 5 things to know
What Trump’s budget proposal means for FDA funding
Baking soda shortage forces hospitals to postpone surgeries, treatments
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.